A Phase 1 interventional study of Vedolizumab SC and Vedolizumab IV in Healthy, sponsored by Takeda. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the absolute bioavailability and pharmacokinetics of vedolizumab following a single injection of vedolizumab subcutaneously at 3 varying doses.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to determine its bioavailability, safety, and tolerability in the body with three varying doses of vedolizumab SC compared to people who are administered vedolizumab IV.
The study will enroll approximately 24 non-Japanese patients and 24 Japanese patients. Participants will be randomly assigned to one of the four treatment groups:
All participants will receive the treatment they are assigned on Day 1 of the study.
This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is up to 196 days. Participants will make 10 visits to the clinic, including one 8 day period of confinement to the clinic, and will be contacted by telephone at Study Day 168 (+/-3), approximately 6 months after dose for a follow-up questionnaire.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab SC, once on Day 1.
Drug: Vedolizumab SC
Vedolizumab SC, once on Day 1.
Drug: Vedolizumab SC
Vedolizumab SC, once on Day 1.
Drug: Vedolizumab SC
Vedolizumab IV, once on Day 1.
Drug: Vedolizumab IV
Vedolizumab injection, for subcutaneous use (vedolizumab SC)
Also known as: MLN0002SC
Vedolizumab injection, for intravenous use (vedolizumab IV)
Also known as: MLN0002SC
Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration
Bioavailability is defined as the rate and extent to which the active moiety of the e.g. subcutaneous administered drug reaches the systemic circulation. Population mean estimate for bioavailability was based on population pharmacokinetic (PK) analysis to find one measure. The exposure data were pooled across visits and subjects to identify population PK parameter estimates and covariate effects. The outcome measure data was planned to be analyzed using a model collating all arms measures to report pooled data across arms, as per planned analysis. Bioavailability was estimated using population pharmacokinetic (popPK) analysis.
Time frame: Day 1: predose and on multiple time points (up to Day 127)
Participants took part in the study at 1 investigative site in the United Kingdom from 09 June 2014 to 16 January 2015.
| Milestone | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg |
|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
Bioavailability is defined as the rate and extent to which the active moiety of the e.g. subcutaneous administered drug reaches the systemic circulation. Population mean estimate for bioavailability was based on population pharmacokinetic (PK) analysis to find one measure. The exposure data were pooled across visits and subjects to identify population PK parameter estimates and covariate effects. The outcome measure data was planned to be analyzed using a model collating all arms measures to report pooled data across arms, as per planned analysis. Bioavailability was estimated using population pharmacokinetic (popPK) analysis.
| percentage of drug | Vedolizumab Subcutaneous |
|---|---|
| Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration | 0.751 (0.689 to 0.819) |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 168 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab Intravenous 300 mg | — | 0/12 (0%) | 9/12 (75%) |
| Vedolizumab Subcutaneous 54 mg | — | 0/12 (0%) | 8/12 (66.7%) |
| Vedolizumab Subcutaneous 108 mg | — | 0/12 (0%) | 11/12 (91.7%) |
| Vedolizumab Subcutaneous 160 mg | — | 0/12 (0%) | 8/12 (66.7%) |
| Event | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/12 | 3/12 | 3/12 | 0/12 |
| DizzinessNervous system disorders | 1/12 | 0/12 | 0/12 | 3/12 |
| NasopharyngitisInfections and infestations | 2/12 | 2/12 | 2/12 | 3/12 |
| PresyncopeNervous system disorders | 0/12 | 2/12 | 0/12 | 0/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/12 | 0/12 | 2/12 | 0/12 |
| ConstipationGastrointestinal disorders | 0/12 | 1/12 | 0/12 | 0/12 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/12 | 1/12 | 0/12 | 0/12 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 1/12 | 0/12 |
| ToothacheGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 |
| Injection site reactionGeneral disorders | 0/12 | 0/12 | 0/12 | 1/12 |
Safety analysis set included all randomized participants who received study drug.
| Age, Continuous(years) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Mean | 33.9 ± 12.30 | 41.0 ± 13.06 | 31.1 ± 9.59 | 35.2 ± 12.89 | 35.3 ± 12.21 |
| Gender(Participants) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 5 | 5 | 19 |
| Male | 8 | 7 | 7 | 7 | 29 |
| Race/Ethnicity, Customized(participants) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 6 | 24 |
| White | 5 | 6 | 6 | 6 | 23 |
| Multiracial | 1 | 0 | 0 | 0 | 1 |
| Weight(kilogram (kg)) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Mean | 65.8 ± 13.84 | 68.0 ± 12.96 | 67.6 ± 13.42 | 64.3 ± 14.58 | 66.4 ± 13.35 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Mean | 21.8 ± 2.90 | 23.0 ± 2.98 | 22.8 ± 2.44 | 22.0 ± 3.41 | 22.4 ± 2.90 |
| Smoking Classification(participants) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Had Never Smoked | 8 | 9 | 10 | 6 | 33 |
| Current Smoker | 3 | 1 | 2 | 5 | 11 |
| Ex-Smoker | 1 | 2 | 0 | 1 | 4 |
| Alcohol Classification(participants) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Had Never Drunk | 0 | 0 | 1 | 1 | 2 |
| Current Drinker | 11 | 9 | 9 | 9 | 38 |
| Ex-Drinker | 1 | 3 | 2 | 2 | 8 |
| Female Reproductive Status(participants) | Vedolizumab Intravenous 300 mg | Vedolizumab Subcutaneous 54 mg | Vedolizumab Subcutaneous 108 mg | Vedolizumab Subcutaneous 160 mg | Total |
|---|---|---|---|---|---|
| Postmenopausal Female | 0 | 1 | 0 | 0 | 1 |
| Female of Childbearing Potential | 4 | 4 | 5 | 5 | 18 |
| Not Applicable (Participant was Male) | 8 | 7 | 7 | 7 | 29 |
The record gives a start of Jun 2014, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab